| Literature DB >> 25268515 |
Laurent Mosoni1, Eva Gatineau1, Philippe Gatellier2, Carole Migné1, Isabelle Savary-Auzeloux1, Didier Rémond1, Emilie Rocher3, Dominique Dardevet1.
Abstract
Our aim was to compare and combine 3 nutritional stEntities:
Mesh:
Substances:
Year: 2014 PMID: 25268515 PMCID: PMC4182511 DOI: 10.1371/journal.pone.0109098
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Diet composition.
| Casein | Whey | Whey HP | ||||
| Aox− | Aox+ | Aox− | Aox+ | Aox− | Aox+ | |
|
| ||||||
| Casein | 140 | 140 | 0 | 0 | 0 | 0 |
| Whey | 0 | 0 | 140 | 140 | 215 | 215 |
| L-cysteine | 1.8 | 1.8 | 0 | 0 | 0 | 0 |
| Tyrosine | 0 | 0 | 2.3 | 2.3 | 0 | 0 |
| Arginine | 0 | 0 | 1.7 | 1.7 | 0 | 0 |
| Rapeseed oil | 20 | 20 | 20 | 20 | 20 | 20 |
| Sunflower oil | 2 | 2 | 2 | 2 | 2 | 2 |
| Peanut oil | 18 | 18 | 18 | 18 | 18 | 18 |
| Mineral mixture | 35 | 35 | 35 | 35 | 35 | 35 |
| Vitamin mixture | 10 | 10 | 10 | 10 | 10 | 10 |
| Choline bitartrate | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
| Chamomile extract | 0 | 17 | 0 | 17 | 0 | 17 |
| Lactose | 100 | 100 | 86 | 86 | 79 | 79 |
| Sucrose | 127 | 127 | 127 | 127 | 127 | 127 |
| Cellulose | 50 | 40 | 50 | 40 | 50 | 40 |
| Wheat starch | 493.7 | 486.7 | 505.5 | 498.5 | 505.5 | 434.5 |
| Protein | 116 | 116 | 114 | 114 | 175 | 175 |
| Leucine | 10.1 | 10.1 | 13.8 | 13.8 | 21.1 | 21.1 |
| Fat | 42.1 | 42.1 | 41.4 | 41.4 | 42.2 | 42.2 |
| Fibers | 50 | 57 | 50 | 57 | 50 | 57 |
| Energy –kcal/kg | 3783 | 3755 | 3811 | 3783 | 3792 | 3764 |
| Vitamin E - UI/kg | 71 | 300 | 71 | 300 | 71 | 300 |
| Vitamin D - UI/kg | 1000 | 5000 | 1000 | 5000 | 1000 | 5000 |
*Mineral and vitamin mixtures were made according to AIN 93 except in Aox+ rats: in these groups, vitamin E and vitamin D content were increased to provide 300 and 5000 UI/kg diet respectively.
Casein diet was supplemented with cysteine according to AIN 93. We considered that the AIN 93 diet corresponded to the basal requirements of rats, thus whey diet was supplemented with tyrosine and arginine to provide as much of these two amino acids as the AIN 93 diet.
Figure 1Changes of food intake in all groups during the experimental period.
Six groups were compared: casein fed rats without anti-inflammatory/antioxidant supplementation (cas Aox−); casein fed rats with anti-inflammatory/antioxidant supplementation (cas Aox+); whey protein fed rats without anti-inflammatory/antioxidant supplementation (Whey Aox−); whey protein fed rats with anti-inflammatory/antioxidant supplementation (Whey Aox+); whey protein fed rats without anti-inflammatory/antioxidant supplementation with a high protein content (18% vs 11–12% in other groups) (Whey HP Aox−); whey protein fed rats with anti-inflammatory/antioxidant supplementation with a high protein content (18% vs 11–12% in other groups) (Whey HP Aox+). These different diets were given during 6 months. Food intake fluctuated with time without any discernible trend. Overall, food intake was not significantly different between groups.
Figure 2Changes of body weight in all groups during the experimental period.
See figure 1 for group description. Body weight fluctuated with time without any discernible trend. Overall, body weight was not significantly different between groups.
Evolution of body composition during the experimental period.
| Cas | Whey | Whey HP | ||||
| Aox− | Aox+ | Aox− | Aox+ | Aox− | Aox+ | |
|
| g | |||||
| Before | 660±19 | 642±20 | 649±16 | 642±14 | 638±13 | 641±18 |
| After | 653±20 | 637±15 | 645±17 | 634±16 | 641±12 | 642±14 |
|
| % body weight | |||||
| Before | 71.5±1.3 | 72.8±1.6 | 72.4±1.4 | 72.6±1.3 | 73.6±0.9 | 72.9±1.0 |
| After | 69.7±1.6 | 69.0±1.6 | 69.9±1.6 | 69.5±1.3 | 71.2±0.7 | 70.7±1.2 |
|
| ||||||
| Before | 469±11 | 462±11 | 468±8 | 464±9 | 468±9 | 466±13 |
| After | 450±10 | 437±10 | 446±6 | 438±10 | 455±7 | 451±9 |
| % change | −3.7±1.5 | −5.3±1.0 | −4.4±0.7 | −5.5±1.3 | −2.6±0.9 | −2.5±1.2 |
|
|
| |||||
| Before | 28.5±1.3 | 27.2±1.6 | 27.6±1.4 | 27.4±1.3 | 26.4±0.9 | 27.2±1.0 |
| After | 30.6±1.6 | 31.0±1.6 | 30.1±1.6 | 30.5±1.3 | 28.9±0.7 | 29.3±1.2 |
|
| ||||||
| Before | 191±13 | 179±15 | 183±14 | 178±11 | 170±8 | 175±9 |
| After | 203±15 | 200±12 | 200±16 | 196±12 | 186±7 | 190±11 |
| % change | +7.8±5.9 | +18.0±6.5 | +11.3±5.7 | +12.9±5.1 | +12.7±4.5 | +11.0±4.9 |
“Body W” is body weight, “LBM” is lean body mass, “% change” is the modification of total lean body mass or total fat mass during the experimental period. ↓*: Main effect “time” of variance analysis was significant for lean body mass expressed in g (P<0.01). ↑* Main effect “time” of variance analysis was significant for fat mass expressed in g and in % body weight (P<0.01).
Main effect “protein level” of variance analysis was significant for % change of lean body mass (P = 0.03).
Regarding post hoc mean comparisons, there was never a significant difference between means with P<0.05.
Comparison of tissue weights in nutritional groups at the end of the experimental period.
| Cas | Whey | Whey HP | ||||
| Weight | Aox− | Aox+ | Aox− | Aox+ | Aox− | Aox+ |
|
| ||||||
| Gastrocnemius | 4.40±0.17 | 4.60±0.16 | 4.75±0.16 | 4.68±0.16 | 4.64±0.18 | 4.80±0.19 |
| Tibialis ante. | 1.33±0.06 | 1.35±0.05 | 1.43±0.05 | 1.40±0.06 | 1.38±0.05 | 1.42±0.06 |
| EDL - mg | 457±15 | 449±13 | 463±14 | 469±15 | 451±18 | 459±15 |
| Soleus - mg | 444±20 | 497±16 | 470±19 | 465±21 | 454±25 | 463±29 |
| Sum | 6.63±0.25 | 6.90±0.22 | 7.12±0.22 | 7.02±0.23 | 6.92±0.25 | 7.14±0.27 |
| Liver | 15.6 | 17.5 | 15.2 | 17.6 | 14.7 | 16.7 |
| Kidneys | 3.7 | 4.0 | 3.4 | 3.8 | 3.6 | 3.8 |
| Spleen | 1.37±0.08 | 1.32±0.06 | 1.42±0.05 | 1.32±0.04 | 1.35±0.06 | 1.29±0.05 |
| Heart | 1.71±0.06 | 1.72±0.04 | 1.73±0.06 | 1.69±0.03 | 1.71±0.05 | 1.71±0.04 |
| Perirenal AT | 19.5±1.6 | 17.4±1.0 | 19.7±1.7 | 19.4±1.3 | 18.8±1.3 | 16.4±1.2 |
| Perigenital AT | 15.5±1.2 | 14.7±1.4 | 15.5±1.1 | 15.3±0.7 | 15.7±0.8 | 13.4±0.9 |
«Tibialis ante.» = tibialis anterior; «EDL» = extensor digitorum longus; «AT» = adipose tissue.
*: The only significant effects were: effect of antioxidant supplementation on liver weight (P<0.01) and on kidney weight (P<0.05).
: mean values affected with the same letter were not significantly different.
Figure 3Fibrinogen and α2-macroglobulin plasma levels at the end of the experimental period.
See figure 1 for group description. a,b,c…: means affected with the same letters were not significantly different. A: Fibrinogen values are expressed in % of the value measured at the beginning of the experiment. #: main effect “protein level” of variance analysis was significant (P = 0.04). B: α2-macroglobulin values are expressed in mg/L. Variance analysis detected a trend (P = 0.09) for main effect “anti-inflammatory/antioxidant supplementation”.
Oxidative stress parameters in gastrocnemius muscle, liver and plasma at the end of the nutritional period.
| Cas | Whey | Whey HP | ||||
| Aox− | Aox+ | Aox− | Aox+ | Aox− | Aox+ | |
|
| ||||||
| Glutathione | 0.63±0.04 | 0.64±0.04 | 0.69±0.03 | 0.69±0.03 | 0.69±0.03 | 0.72±0.03 |
| SOD activity | 6.0±0.3 | 5.5±0.2 | 5.7±0.3 | 5.5±0.4 | 5.8±0.2 | 5.8±0.2 |
| TAC | 0.16±0.03 | 0.13±0.01 | 0.15±0.02 | 0.12±0.02 | 0.17±0.03 | 0.13±0.02 |
| Carbonyls | 2.60±0.09 | 2.56±0.06 | 2.64±0.10 | 2.56±0.06 | 2.60±0.08 | 2.53±0.10 |
| TBARS* | 0.79 | 0.65 | 0.70 | 0.56 | 0.71 | 0.70 |
|
| ||||||
| Glutathione* | 6.4 | 9.0 | 6.3 | 9.1 | 6.2 | 8.8 |
| SOD activity | 17.9 | 17.5 | 16.0 | 14.5 | 15.0 | 14.7 |
| TAC | 0.96±0.08 | 0.91±0.08 | 0.92±0.09 | 0.81±0.08 | 0.86±0.06 | 0.92±0.08 |
|
| ||||||
| TAC* | 0.88 | 0.98 | 0.89 | 0.97 | 0.92 | 0.98 |
Glutathione content was expressed in µmoles/g tissue, SOD activity in U/mg protein, TAC ( = total antioxidant capacity) in moles of trolox equivalent/g protein, carbonyls in nmoles DNPH/mg protein, TBARS (thiobarbituric acid-reactive substances) in mg/kg tissue. Variance analysis detected a significant effect of *polyphenol/antioxidant supplementation (P
: protein nature (casein vs Whey)(P<0.01).
: mean values affected with the same letter were not significantly different.
Muscle protein metabolism at the end of the nutritional period.
| Cas | Whey | Whey HP | ||||
| Aox− | Aox+ | Aox− | Aox+ | Aox− | Aox+ | |
|
| ||||||
| PA | 6.67±0.43 | 6.23±0.29 | 6.18±0.28 | 6.30±0.44 | 6.35±0.26 | 5.95±0.21 |
| PP | 6.87±0.36 | 7.05±0.46 | 6.86±0.46 | 6.32±0.27 | 6.98±0.31 | 6.07±0.41 |
|
| ||||||
| PA | 0.31±0.01 | 0.36±0.02 | 0.35±0.02 | 0.36±0.03 | 0.36±0.02 | 0.33±0.01 |
| PP | 0.40 | 0.35±0.02 | 0.39 | 0.38 | 0.38 | 0.37±0.05 |
| 0 mM leu | 0.28 | 0.28 | 0.32 | 0.32 | 0.31 | 0.31 |
| 200 mM leu | 0.33 | 0.33 | 0.32 | 0.34 | 0.36 | 0.35 |
|
| ||||||
| PA | 1.33±0.08 | 1.26±0.06 | 1.30±0.07 | 1.29±0.04 | 1.22±0.04 | 1.23±0.05 |
| PP | 1.36±0.08 | 1.27±0.10 | 1.29±0.08 | 1.23±0.08 | 1.18±0.06 | 1.17±0.08 |
Values are expressed in means ± SE. PA = post-absorptive state. PP = post-prandial state. 0 or 200 mM leu: epitrochlearis muscles were incubated in medium containing either 0 or 200 mM leucine. In vivo S = in vivo gastrocnemius muscle fractional synthesis rates, expressed in %/day; the only significant effect detected by variance analysis was the effect of feeding (P = 0.045); however, there was no significant differences between means. Ex-vivo S = ex-vivo epitrochlearis muscle synthesis rates, expressed in µmoles phenylalanine/mg prot/h; experiment 1, PA/PP states: the only significant effect detected by variance analysis was the effect of feeding (P = 0.01);
= significantly different from Cas Aox− PA mean value;
= significantly different from Whey HP Aox+ PA; experiment 2, 0 or 200 mM leu: the only significant effect detected by variance analysis were the effect of leucine (P<0.001) and protein type (P = 0.04);
= significantly different from Cas Aox− 0 mM leu and Cas Aox+ 0 mM leu;
= significantly different from Whey HP Aox− 200 mM leu and Whey HP Aox+ 200 mM leu;
Ex-vivo P = ex-vivo epitrochlearis muscle proteolysis rates, expressed in µmoles tyrosine/mg prot/h; variance analysis showed that only protein level modulated proteolysis rates (Whey HP vs all other groups); it reached significance (P = 0.03) when only nutritional state and protein level were included in the model; there was no significant differences between means.
Figure 4Focus on the effect of the level of protein intake on muscle protein metabolism.
(see Table 5 for detailed data per group). We pooled data to focus on the effect of the level of protein intake to analyze how modifications of muscle protein metabolism could be in accordance with the fact that increasing whey protein intake slowed the age-related loss of lean body mass. NP: diet contained 12% casein or whey protein; HP: diet contained 18% whey protein; PA = post-absorptive state; PP: post prandial state. a,b,c…: means affected with the same letters were not significantly different. A: ex-vivo epitrochearis muscle protein synthesis rates (µmoles phenylalanine incorporated per mg protein and per hour). B: in vivo gastrocnemius muscle protein synthesis rates (fractional synthesis rates, %/day). C: leucine effect on ex-vivo epitrochlearis muscle protein synthesis rates (µmoles phenylalanine incorporated per mg protein and per hour). D: ex-vivo epitrochlearis muscle proteolysis rates (µmoles tyrosine released per mg protein and per hour). A, B, C: Variance analysis detected a significant effect of feeding (P<0.05). It was “protein level” for D (P = 0.03 if only “protein level” and “nutritional state” were included as main effects in variance analysis). See Table 5 for detailed group comparisons.